122 related articles for article (PubMed ID: 9734899)
1. Tackling the real culprits in Crohn's disease.
Bonn D
Lancet; 1998 Jun; 351(9117):1710. PubMed ID: 9734899
[No Abstract] [Full Text] [Related]
2. Crohn's trial shows the pros of antisense.
Robertson D
Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
[No Abstract] [Full Text] [Related]
3. Drug treatment for Crohn's disease.
Yacyshyn BR
Lancet; 1998 Aug; 352(9129):743. PubMed ID: 9729027
[No Abstract] [Full Text] [Related]
4. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
Yacyshyn BR; Bowen-Yacyshyn MB; Jewell L; Tami JA; Bennett CF; Kisner DL; Shanahan WR
Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
[TBL] [Abstract][Full Text] [Related]
7. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
Yacyshyn BR; Schievella A; Sewell KL; Tami JA
Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
[TBL] [Abstract][Full Text] [Related]
8. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
9. Genetic therapy for transplant vascular sclerosis.
Bennett CF; Stepkowski SM
Transpl Immunol; 1997 Dec; 5(4):299-302. PubMed ID: 9504151
[No Abstract] [Full Text] [Related]
10. Antisense oligonucleotides in lung cancer.
Pujol JL; Jacot W
Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
[No Abstract] [Full Text] [Related]
11. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
Schreiber S; Nikolaus S; Malchow H; Kruis W; Lochs H; Raedler A; Hahn EG; Krummenerl T; Steinmann G;
Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
[TBL] [Abstract][Full Text] [Related]
12. Alicaforsen. Isis Pharmaceuticals.
Gewirtz AT; Sitaraman S
Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide treatment of inflammatory bowel diseases.
Yacyshyn BR
Methods Mol Med; 2005; 106():295-305. PubMed ID: 15375323
[No Abstract] [Full Text] [Related]
14. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice.
Neurath MF; Pettersson S; Meyer zum Büschenfelde KH; Strober W
Nat Med; 1996 Sep; 2(9):998-1004. PubMed ID: 8782457
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
Green DW; Roh H; Pippin J; Drebin JA
J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188
[No Abstract] [Full Text] [Related]
16. ISIS 2302. Oligo-TCS.
Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
[No Abstract] [Full Text] [Related]
17. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
18. GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
Agrawal S; Tang JY
Antisense Res Dev; 1992; 2(4):261-6. PubMed ID: 1363378
[No Abstract] [Full Text] [Related]
19. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
20. Technology evaluation: ISIS-104838, OraSense.
Kennewell P
Curr Opin Mol Ther; 2003 Feb; 5(1):76-80. PubMed ID: 12669475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
